Ulcerative colitis – PubMed

Declaration of interests

RCU has no conflicts of interest. SM has served as a consultant for Pfizer Inc and receives research funding support from Takeda Pharmaceuticals. PBA has received Speaker fees for MSD, AbbVie, Allergen, Ferring, Warner Chilcott, and Napp. LP-B has received consulting fees from Merck, AbbVie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Therakos, Pharmacosmos, Pilge, Bristol-Myers Squibb, Union Chimique Belge (UCB) Pharmaceuticals, Hospira, Celltrion, Takeda, Biogaran, Boerhinger-Ingelheim, Lilly, Pfizer, HAC Pharma, Index Pharmaceuticals, Amgen, Sandoz, Forward Pharma GmbH, Celgene, Biogen, Lycera, and Samsung Bioepis, and lecture fees from Merck, AbbVie, Takeda, Janssen, Takeda, Ferring, Norgine, Tillots, Vifor, Therakos, Mitsubishi, and HAC Pharma. J-FC has served as consultant or advisory board member for AbbVie, Amgen, AstraZeneca, ABScience, Boehringer, Bristol-Meyers Squibb, Celgene, Celltrion, Danone, Enterome, Evidera, Ferring, Genentech, Giuliani SPA, Given Imaging, Janssen & Janssen, Immune Pharmaceuticals, Intestinal Biotech Development, Kyowa Kirin Pharma, Lilly, Medimmune, Merck Sharp Dohme, Merck & Co, Millennium Pharmaceuticals Inc, Navigant Consulting, Neovacs, Nestle Nutrition Sciences Partner, Nutrition Science Partners Ltd, Pfizer, Prometheus Laboratories, Protagonist Therapies, Receptos, Sanofi, Schering Plough Corporation, Second Genome, Shire, Takeda, Teva Pharmaceuticals, Tigenix, UCB, UEGW AbbVie Advisory Board, UEGW AbbVie Symposium, Vertex, and Dr August Wolff GmbH Co.

View original post here:
Ulcerative colitis - PubMed